Guardant Health Investor Presentation
LUNAR- 1: Detection of post-op residual disease in CRC and NSCLC
Study of colorectal cancer patients over 5 years
•
Design
•
Retrospective surgical CRC study with 5 year follow-up
Patients going through curative-intent hepatectomy
Study of resected early-stage NSCLC
Prospective, comprehensive profiling 19.4 months follow-up
Design
ctDNA assessment of MRD pre- and post-op at 4 weeks and until
recurrence
Results
Residual Free Survival
10
0.8
0.6
0.4
0.2
not detected
detected
0.0-
30
0
10
20
40
50
Months
ctDNA detected in 84% of pre-op samples
All patients with detected ctDNA using LUNAR assay post-op
relapsed (48% sens / 100% spec)
Results
•
Recurrence free survival (% of patients)
1.00-
0.75-
0.50-
4wk ctDNA not detected
0.25-
4wk ctDNA detected
HR 4.68 (1.55 - 14.16)
p = 0.003 by log-rank
0.00-
12
18
24
Months
H
Somatic panel with classifier to filter non-tumor variants
ctDNA detected in 69% evaluable patients prior to/at time of
recurrence
ctDNA detected post-op four months earlier than radiographic
recurrence
Overman (Kopetz) et al. Jun 2018 J Clin Oncol 36, 2018 (suppl; abstr 12044)
Lam (Heymach) et al. Sep 2018 WCLC
24
GUARDANTView entire presentation